More than Half of Cancer Patients Still Alive Post CAR-T Therapy

Around 51 per cent of patients suffering from diffuse large B-cell lymphoma (DLBCL) were still alive after 2 years of treatment with an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel.

Treating patients having diffuse large B-cell lymphoma (DLBCL) with an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel, an approved drug by the US Food and Drug Administration, was proved to be effective. Around 51 per cent of patients were still alive post-treatment.//

The study, co-led by Sattva Neelapu, M.D., professor of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, reported its findings in the Dec. 2 online issue of The Lancet Oncology and during a presentation at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego.

Follicular Lymphoma - Causes, Symptoms, Diagnosis, Treatment and Prevention
Follicular lymphoma is a slow growing cancer of the lymph nodes. It is the most common form of slow growing B-cell non-Hodgkin’s lymphoma.

‘Axi-cel is known to have a long-term remission effect on cancer in people who underwent the trial.’

"This two-year assessment demonstrates that axi-cel can induce durable remissions in a substantial proportion of patients with an acceptable long-term safety profile," said Neelapu. "There also is evidence of gradual B-cell recovery in most patients with refractory large B-cell lymphoma who otherwise have limited treatment options."

With a median follow-up of 27.1 months for 101 patients enrolled in Phase II, the study found that 83 percent of patients achieved a reduction in cancer activity tied to treatment, known as an objective response; 58 percent had no detectable cancer or a complete response, and 39 percent reported ongoing responses. Median overall survival was not reached, and no axi-cel related adverse effects were reported after the 12-month period.

The results mirrored findings of a previously reported median follow up of 15.4 months at which time objective response rate was 82 percent, complete response rate was 58 percent, with 42 percent of patients reporting ongoing responses.

Burkitt’s Lymphoma - Symptoms - Signs - Diagnosis - Treatment - FAQs
Burkitt’s lymphoma is a rare type of non-hodgkin’s lymphoma that commonly affects children. It usually begins in the abdominal region.

In addition, exploratory analyses were performed to assess CAR T-cell persistence and B-cell recovery in patients with ongoing remission, and at 24 months, persisting CAR gene-marked cells were observed in 66 percent of patients with evaluable biomarker samples. Peripheral blood B-cells were measurable in 75 percent of patients.

'Real-world' outcomes support ZUMA-1 findings

Hodgkins Lymphoma - Incidence Causes Diagnosis Types Treatment FAQs
Hodgkins lymphoma or Hodgkins disease has the distinction of being the first cancer to be cured by chemotherapy or by radiotherapy.

A subsequent "real-world" assessment of 274 patients who received axi-cel, post FDA-approval of the therapy revealed similar results to the overall ZUMA-1 study. The real-world retrospective study included 17 centers that contributed data independent from the manufacturer-funded trial.

Findings from the study, led by Loretta Nastoupil, M.D., assistant professor of Lymphoma & Myeloma, were presented Dec. 1 at the ASH Annual Meeting & Exposition. By day 90, the real-world assessment reported 81 percent of patients had an objective response and 57 percent had a complete response.

Non-Hodgkins Lymphoma
Non Hodgkins Lymphoma is a cancer that affects the lymph tissues. It is made up of a wide array of subtypes.

"Although limited by a relatively short follow up, 90-day responses in the real-world setting are comparable to the best responses observed in the pivotal ZUMA-1 clinical trial," said Nastoupil. "Importantly, safety appears comparable to the ZUMA-1 trial despite nearly half of patients failing to meet ZUMA-1 eligibility criteria."

Source-Eurekalert